Polar Capital Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$85.3M	Buy	257,674 +17,068	+7%	+$5.81M	0.37%	71
2025 Q4	$95.7M	Sell	240,606 -10,854	-4%	-$4.8M	0.44%	71
2025 Q3	$115M	Buy	251,460 +13,960	+6%	+$5.68M	0.55%	55
2025 Q2	$77.4M	Sell	237,500 -42,500	-15%	-$11.8M	0.41%	67
2025 Q1	$75.6M	Sell	280,000 -30,000	-10%	-$7.71M	0.46%	65
2024 Q4	$72.9M	Hold	310,000	–	–	0.41%	63
2024 Q3	$85.3M	Buy	310,000 +25,000	+9%	+$6.51M	0.41%	55
2024 Q2	$69.3M	Buy	285,000 +50,000	+21%	+$7.89M	0.41%	68
2024 Q1	$35.1M	Buy	235,000 +50,000	+27%	+$8.34M	0.18%	106
2023 Q4	$35.4M	Sell	185,000 -50,000	-21%	-$8.52M	0.22%	101
2023 Q3	$41.6M	Hold	235,000	–	–	0.31%	84
2023 Q2	$44.6M	Sell	235,000 -76,918	-25%	-$15.2M	0.31%	93
2023 Q1	$62.5M	Buy	311,918 +14,418	+5%	+$3.03M	0.46%	71
2022 Q4	$70.7M	Buy	297,500 +182,500	+159%	+$38.9M	0.56%	53
2022 Q3	$23K	Sell	115,000 -98,079	-46%	-$18.7M	0.15%	132
2022 Q2	$31.1K	Sell	213,079 -16,754	-7%	-$2.38M	0.18%	110
2022 Q1	$37.5K	Sell	229,833 -305,798	-57%	-$46.6M	0.17%	110
2021 Q4	$90.8K	Buy	535,631 +11,919	+2%	+$2.22M	0.37%	62
2021 Q3	$98.9K	Buy	523,712 +195,430	+60%	+$36.7M	0.44%	53
2021 Q2	$55.6K	Buy	328,282 +129,782	+65%	+$19M	0.24%	95
2021 Q1	$28M	Sell	198,500 -3,500	-2%	-$527K	0.17%	130
2020 Q4	$26.3M	Buy	+202,000	New	+$27M	0.17%	131